Literature DB >> 18006792

Newer pathologic assessment techniques for colorectal carcinoma.

Roderick R Turner1, Carolyn Li, Carolyn C Compton.   

Abstract

The pathogenesis of colorectal carcinoma is characterized by progressive genetic abnormalities, which lead to proteomic and cellular changes that determine the cancer malignant phenotype. Phenotypic characteristics seen on histopathologic examination (e.g., tumor stage, histologic grade, and vasoinvasiveness) are essential to planning patient management and should continue to be the major focus of pathologists' efforts. Nonetheless, additional markers that improve the prognostic and predictive power of the pathologic analysis of the primary tumor have been the focus of intense research in recent years. Improved prognostic power may derive from advancements in histopathologic evaluation, more sensitive lymph node staging techniques, and specific molecular analysis methods, such as genetic tests or immunophenotypic profiles. Histopathologic improvements are needed to better standardize histologic grade determination and recognize tumor budding at the invasive front as a marker of aggressive biological behavior and an adverse parameter. Ultrastaging of mesenteric lymph nodes remains a controversial area. Genotypic studies are well developed in the areas of microsatellite instability and chromosome 18q deletion/loss of heterozygosity. Immunophenotypic studies are available in a range of areas including tumor suppressor gene/oncogene expression, proliferation/apoptosis, angiogenesis, and cell adhesion and signaling. Gene expression profiles identified by microarray techniques may help to subtype the large category of microsatellite-stable colorectal carcinoma and define immunophenotypic panels to subclassify tumors into prognostic and therapeutic groups. This brief review discusses the most promising of these approaches and evidence supporting their potential clinical utility.

Entities:  

Mesh:

Year:  2007        PMID: 18006792     DOI: 10.1158/1078-0432.CCR-07-1151

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression.

Authors:  Shin Fujita; Hirokazu Taniguchi; Takashi Yao; Tadakazu Shimoda; Hideki Ueno; Takashi Hirai; Masayuki Ohue
Journal:  Int J Colorectal Dis       Date:  2010-03-05       Impact factor: 2.571

2.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

3.  Previstage GCC test for staging patients with colorectal cancer.

Authors:  Alex Mejia; Scott A Waldmana
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

Review 4.  Pathologic processing of the total mesorectal excision.

Authors:  Molly Campa-Thompson; Robert Weir; Natalie Calcetera; Philip Quirke; Susanne Carmack
Journal:  Clin Colon Rectal Surg       Date:  2015-03

5.  Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients.

Authors:  Andreia de Albuquerque; Ilja Kubisch; Ulrich Stölzel; Dominikus Ernst; Joachim Boese-Landgraf; Georg Breier; Gudrun Stamminger; Nikos Fersis; Sepp Kaul
Journal:  J Transl Med       Date:  2012-11-13       Impact factor: 5.531

Review 6.  Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  Oncotarget       Date:  2010-11

7.  High-Grade Tumor Budding Stratifies Early-Stage Cervical Cancer with Recurrence Risk.

Authors:  Bangxing Huang; Jing Cai; Xia Xu; Shuang Guo; Zehua Wang
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

8.  Two-marker protein profile predicts poor prognosis in patients with early rectal cancer.

Authors:  I Zlobec; K Baker; L Terracciano; S Peter; L Degen; C Beglinger; A Lugli
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

9.  Prognostic value of poorly differentiated clusters in invasive breast cancer.

Authors:  Ying Sun; Fenli Liang; Wei Cao; Kai Wang; Jianjun He; Hongyan Wang; Yili Wang
Journal:  World J Surg Oncol       Date:  2014-10-12       Impact factor: 2.754

10.  Prognostic significance of CD168 overexpression in colorectal cancer.

Authors:  Ke Wang; Tao Zhang
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.